Ling Li
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Ling Li has a total of 394 co-authors. Here are the top co-authors by number of shared publications:
Liang Qi
12 shared publicationsYingqi Lv
Department of Endocrinology, Zhongda Hospital, School of Medicine, Southeast University, Nanjing, 210009, China; Key Laboratory of Environmental Medicine Engineering of Ministry of Education, Southeast University, Nanjing, 210009, China
12 shared publicationsXiangyun Zhu
Department of Endocrinology, Zhongda Hospital, School of Medicine, Southeast University, Nanjing, China
11 shared publicationsDechen Liu
Department of Endocrinology, Zhongda Hospital, School of Medicine, Southeast University, Nanjing, China
10 shared publications- Stepehen Jacob Pandol
Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA
10 shared publications Qiong Wei
Department of Endocrinology, Zhongda Hospital, School of Medicine, Southeast University, Nanjing, China
9 shared publications
Latest Publications
- Open Access
Integrated Plasma Proteomic and Single-Cell Transcriptomic Profiling of Three COVID-19 Second-Booster Regimens: An Exploratory Analysis of a Randomized Phase IV Trial
Background: Waning vaccine-induced immunity and the emergence of SARS-CoV-2 variants have prompted the evaluation of alternative booster strategies. We investigated the systemic immune profiles associated with three second-booster regimens in adults previously vaccinated with three doses of an inactivated vaccine. Methods: This exploratory analysis was nested within a randomized phase IV trial comparing homologous CoronaVac (ICV), intramuscular Ad5-nCoV (IM), and inhaled Ad5-nCoV (IH) boosting. Serum antibody responses were assessed, 119 plasma samples underwent Olink inflammatory-protein profiling, and 24 peripheral blood mononuclear cell samples were analyzed by single-cell RNA sequencing. Results: At Day 14, wild-type SARS-CoV-2 neutralizing antibody geometric mean titers were 880.8, 297.6, and 77.3 in the IM, IH, and ICV groups, respectively. Seven inflammatory proteins were upregulated in both Ad5-nCoV groups, and several were positively associated with antibody responses. In the small scRNA-seq subset, the IH group showed a higher observed peripheral CD8+ T cell proportion than the IM and ICV groups, together with antigen presentation- and cytotoxicity-related transcriptional patterns; neither vaccine-specific lymphocyte responses nor cellular function was directly measured. Conclusions: The three booster regimens were associated with distinct Day 14 humoral, inflammatory protein, and peripheral immune cell profiles. These hypothesis-generating observations complement the immunogenicity findings of the parent trial but do not establish a causal mechanism or identify a clinically preferred booster regimen.
Open AccessIntegrated Plasma Proteomic and Single-Cell Transcriptomic Profiling of Three COVID-19 Second-Booster Regimens: An Exploratory Analysis of a Randomized Phase IV Trial
Background: Waning vaccine-induced immunity and the emergence of SARS-CoV-2 variants have prompted the evaluation of alternative booster strategies. We investigated the systemic immune profiles associated with three second-booster regimens in adults previously vaccinated with three doses of an inactivated vaccine. Methods: This exploratory analysis was nested within a randomized phase IV trial comparing homologous CoronaVac (ICV), intramuscular Ad5-nCoV (IM), and inhaled Ad5-nCoV (IH) boosting. Serum antibody responses were assessed, 119 plasma samples underwent Olink inflammatory-protein profiling, and 24 peripheral blood mononuclear cell samples were analyzed by single-cell RNA sequencing. Results: At Day 14, wild-type SARS-CoV-2 neutralizing antibody geometric mean titers were 880.8, 297.6, and 77.3 in the IM, IH, and ICV groups, respectively. Seven inflammatory proteins were upregulated in both Ad5-nCoV groups, and several were positively associated with antibody responses. In the small scRNA-seq subset, the IH group showed a higher observed peripheral CD8+ T cell proportion than the IM and ICV groups, together with antigen presentation- and cytotoxicity-related transcriptional patterns; neither vaccine-specific lymphocyte responses nor cellular function was directly measured. Conclusions: The three booster regimens were associated with distinct Day 14 humoral, inflammatory protein, and peripheral immune cell profiles. These hypothesis-generating observations complement the immunogenicity findings of the parent trial but do not establish a causal mechanism or identify a clinically preferred booster regimen.
- Open Access
- 27 October 2026
- Published by Springer Nature in BMC Endocrine Disorders
Association between MASLD and macrovascular alteration in patients with type 2 diabetes mellitus
- 27 October 2026
- Published by Springer Nature in BMC Endocrine Disorders
Open AccessAssociation between MASLD and macrovascular alteration in patients with type 2 diabetes mellitus
- 21 September 2026
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 28 (12) , 11710-11720
Association of Phenotypic Age Acceleration With Pancreatic Fat Percentage in a UK Biobank Imaging Population
Background: Excessive pancreatic fat is associated with metabolic disorders. Phenotypic age acceleration, derived from routine clinical biomarkers, reflects multisystem physiological deviation beyond chronological age. This study examined whether phenotypic ageing is associated with pancreatic fat percentage in a UK population. Methods: This study included 23 558 UK Biobank participants who attended the initial assessment and the first imaging visit. Phenotypic age acceleration was defined as the residual from regressing phenotypic age on chronological age, both obtained at the initial assessment. A positive acceleration value means that an individual is biologically older than their chronological age. Pancreatic fat was quantified as the proton density fat fraction (PDFF) derived from abdominal MRI. Generalised linear models with a gamma distribution and log link were constructed to estimate the association between phenotypic age acceleration and pancreatic PDFF. Subgroup and sensitivity analyses were performed. Results: A total of 8559 (36.3%) people were identified as biologically older. Each 1‐year increase in phenotypic age acceleration was associated with a 2% (mean ratio = 1.02, 95% CI: 1.02, 1.03) higher mean pancreatic PDFF in multivariable‐adjusted models. People in the highest quartile of phenotypic age acceleration had a 37% (mean ratio = 1.37, 95% CI: 1.33, 1.40) higher mean pancreatic PDFF than those in the lowest quartile. Subgroup analyses showed broadly consistent associations. Interactions were observed for sex and non‐fasting triglycerides, but results were comparable. Sensitivity analyses showed consistent results. Conclusions: Phenotypic age acceleration was associated with higher mean pancreatic fat percentage in a large UK Biobank imaging population. Longitudinal studies with repeated imaging assessments are required to determine temporality and clinical relevance.
- 21 September 2026
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 28 (12) , 11710-11720
Association of Phenotypic Age Acceleration With Pancreatic Fat Percentage in a UK Biobank Imaging Population
Background: Excessive pancreatic fat is associated with metabolic disorders. Phenotypic age acceleration, derived from routine clinical biomarkers, reflects multisystem physiological deviation beyond chronological age. This study examined whether phenotypic ageing is associated with pancreatic fat percentage in a UK population. Methods: This study included 23 558 UK Biobank participants who attended the initial assessment and the first imaging visit. Phenotypic age acceleration was defined as the residual from regressing phenotypic age on chronological age, both obtained at the initial assessment. A positive acceleration value means that an individual is biologically older than their chronological age. Pancreatic fat was quantified as the proton density fat fraction (PDFF) derived from abdominal MRI. Generalised linear models with a gamma distribution and log link were constructed to estimate the association between phenotypic age acceleration and pancreatic PDFF. Subgroup and sensitivity analyses were performed. Results: A total of 8559 (36.3%) people were identified as biologically older. Each 1‐year increase in phenotypic age acceleration was associated with a 2% (mean ratio = 1.02, 95% CI: 1.02, 1.03) higher mean pancreatic PDFF in multivariable‐adjusted models. People in the highest quartile of phenotypic age acceleration had a 37% (mean ratio = 1.37, 95% CI: 1.33, 1.40) higher mean pancreatic PDFF than those in the lowest quartile. Subgroup analyses showed broadly consistent associations. Interactions were observed for sex and non‐fasting triglycerides, but results were comparable. Sensitivity analyses showed consistent results. Conclusions: Phenotypic age acceleration was associated with higher mean pancreatic fat percentage in a large UK Biobank imaging population. Longitudinal studies with repeated imaging assessments are required to determine temporality and clinical relevance.
- Open Access
- 13 November 2025
- Published by Springer Nature in Signal Transduction and Targeted Therapy
- Vol. 10 (1) , 1-9
Catheter-based endovascular celiac and hepatic denervation for type 2 diabetes: a multicenter, open-label, single-arm study
Sympathetic hyperactivity is crucial driving factor for hyperglycemia in type 2 diabetes (T2D). We conducted a multicenter, open-label, single-arm trial to evaluate the safety and efficacy of endovascular denervation (EDN) targeting the celiac and hepatic arteries in patients with poorly controlled T2D, defined as glycated hemoglobin (HbA1c) > 7.5% and P < 0.001), with reductions of 1.0%, 1.2%, and 0.9% at 1, 3, and 12 months post-EDN, respectively. Time in range (3.9–10.0 mmol/L) increased by 15.4%, 14.9%, 7.6% and 11.7% at each follow-up time point. Blood pressure also showed reductions during follow-up. Adverse events were reported in 11 (37%) patients, with mild to moderate gastrointestinal symptoms being the most common. These exploratory findings provide a rationale for further evaluating the efficacy of EDN in improving glycemic control in T2D patients through randomized controlled trials.
- 13 November 2025
- Published by Springer Nature in Signal Transduction and Targeted Therapy
- Vol. 10 (1) , 1-9
Open AccessCatheter-based endovascular celiac and hepatic denervation for type 2 diabetes: a multicenter, open-label, single-arm study
Sympathetic hyperactivity is crucial driving factor for hyperglycemia in type 2 diabetes (T2D). We conducted a multicenter, open-label, single-arm trial to evaluate the safety and efficacy of endovascular denervation (EDN) targeting the celiac and hepatic arteries in patients with poorly controlled T2D, defined as glycated hemoglobin (HbA1c) > 7.5% and P < 0.001), with reductions of 1.0%, 1.2%, and 0.9% at 1, 3, and 12 months post-EDN, respectively. Time in range (3.9–10.0 mmol/L) increased by 15.4%, 14.9%, 7.6% and 11.7% at each follow-up time point. Blood pressure also showed reductions during follow-up. Adverse events were reported in 11 (37%) patients, with mild to moderate gastrointestinal symptoms being the most common. These exploratory findings provide a rationale for further evaluating the efficacy of EDN in improving glycemic control in T2D patients through randomized controlled trials.
- Open Access
Bio‐Inspired Pancreas With Microfluidic Multi‐Component Hydrogel Microfibers for Exploring Pancreatic Exocrine and Endocrine Interactions
The rise in pancreatic diseases, resulting from improved living quality and lifestyle habits changes, has imposed a serious social burden. To better understand the pancreatic functions during disease progression, constructing a bionic pancreas is vital yet challenging in tissue engineering. Herein, inspired by the physiological anatomy of the pancreas, we introduce core‐shell microfibers with pancreatic stellate cells (PSCs) in the shell and pancreatic β‐cells in the core. Compared to traditional plate culture, the β‐cells encapsulated in the microfiber exhibit enhanced glucose‐stimulated insulin secretion. Such microfibers also serve as a platform to study the progression of diabetes of the exocrine pancreas, where the PSCs are activated under conditions of pancreatic exocrine diseases such as chronic pancreatitis. The activated PSCs impede insulin synthesis and increase apoptosis in β‐cells, resulting in elevated blood glucose. This high‐glucose microenvironment further exacerbates the activation of PSCs, causing a vicious cycle of diabetes. Additionally, the bio‐inspired pancreas also demonstrates its potential in drug screening, as evidenced by testing the glucagon‐like peptide 1 receptor agonist, Exendin‐4. Building upon such features, it is convincing that these multi‐component microfibers hold promise for exploring the pancreatic exocrine and endocrine interactions, and showing potential in disease modeling, drug screening, and regenerative medicine.
Open AccessBio‐Inspired Pancreas With Microfluidic Multi‐Component Hydrogel Microfibers for Exploring Pancreatic Exocrine and Endocrine Interactions
The rise in pancreatic diseases, resulting from improved living quality and lifestyle habits changes, has imposed a serious social burden. To better understand the pancreatic functions during disease progression, constructing a bionic pancreas is vital yet challenging in tissue engineering. Herein, inspired by the physiological anatomy of the pancreas, we introduce core‐shell microfibers with pancreatic stellate cells (PSCs) in the shell and pancreatic β‐cells in the core. Compared to traditional plate culture, the β‐cells encapsulated in the microfiber exhibit enhanced glucose‐stimulated insulin secretion. Such microfibers also serve as a platform to study the progression of diabetes of the exocrine pancreas, where the PSCs are activated under conditions of pancreatic exocrine diseases such as chronic pancreatitis. The activated PSCs impede insulin synthesis and increase apoptosis in β‐cells, resulting in elevated blood glucose. This high‐glucose microenvironment further exacerbates the activation of PSCs, causing a vicious cycle of diabetes. Additionally, the bio‐inspired pancreas also demonstrates its potential in drug screening, as evidenced by testing the glucagon‐like peptide 1 receptor agonist, Exendin‐4. Building upon such features, it is convincing that these multi‐component microfibers hold promise for exploring the pancreatic exocrine and endocrine interactions, and showing potential in disease modeling, drug screening, and regenerative medicine.
- 2 October 2025
- Published by Elsevier in Journal of Controlled Release
- Vol. 388 (Pt 1) , 114278
Fibrotic collagen-targeted delivery system blocks pancreatic intercellular crosstalk to alleviate pancreatic fibrosis
- 2 October 2025
- Published by Elsevier in Journal of Controlled Release
- Vol. 388 (Pt 1) , 114278
Fibrotic collagen-targeted delivery system blocks pancreatic intercellular crosstalk to alleviate pancreatic fibrosis
- Open Access
- 8 July 2025
- Published by Springer Nature in European Journal of Medical Research
- Vol. 30 (1) , 1-6
Association between serum carcinoembryonic antigen levels and atherosclerotic cardiovascular disease in patients with type 2 diabetes mellitus
Atherosclerotic cardiovascular disease (ASCVD) is cardiovascular disease caused by atherosclerosis. Serum carcinoembryonic antigen (CEA), a common tumor marker, is positively associated with arterial stiffness in healthy adults. Therefore, the aim of this study was to explore the potential association between serum CEA levels and ASCVD in patients with type 2 diabetes mellitus (T2DM). We retrospectively included 1392 patients with T2DM stratified into those with ASCVD and those without ASCVD, and the accumulated data were systematically analyzed between groups. A significant increase in serum CEA levels was observed in T2DM patients with ASCVD compared with those without ASCVD (2.70[1.93–3.98] vs. 2.35[1.60–3.54] ng/mL, p < 0.001). Serum CEA levels were significantly positively correlated with brachial-ankle pulse wave velocity in patients with T2DM (r = 0.151, p < 0.001). Multivariable logistic regression analysis revealed that increased serum CEA levels were independently associated with ASCVD in patients with T2DM (OR = 1.100, 95%CI 1.006–1.203, p = 0.037). Increased serum CEA levels were independently associated with ASCVD in patients with T2DM. The finding highlights that ASCVD may influence the interpretation of serum CEA levels during tumor screening in this population.
- 8 July 2025
- Published by Springer Nature in European Journal of Medical Research
- Vol. 30 (1) , 1-6
Open AccessAssociation between serum carcinoembryonic antigen levels and atherosclerotic cardiovascular disease in patients with type 2 diabetes mellitus
Atherosclerotic cardiovascular disease (ASCVD) is cardiovascular disease caused by atherosclerosis. Serum carcinoembryonic antigen (CEA), a common tumor marker, is positively associated with arterial stiffness in healthy adults. Therefore, the aim of this study was to explore the potential association between serum CEA levels and ASCVD in patients with type 2 diabetes mellitus (T2DM). We retrospectively included 1392 patients with T2DM stratified into those with ASCVD and those without ASCVD, and the accumulated data were systematically analyzed between groups. A significant increase in serum CEA levels was observed in T2DM patients with ASCVD compared with those without ASCVD (2.70[1.93–3.98] vs. 2.35[1.60–3.54] ng/mL, p < 0.001). Serum CEA levels were significantly positively correlated with brachial-ankle pulse wave velocity in patients with T2DM (r = 0.151, p < 0.001). Multivariable logistic regression analysis revealed that increased serum CEA levels were independently associated with ASCVD in patients with T2DM (OR = 1.100, 95%CI 1.006–1.203, p = 0.037). Increased serum CEA levels were independently associated with ASCVD in patients with T2DM. The finding highlights that ASCVD may influence the interpretation of serum CEA levels during tumor screening in this population.
- 16 June 2025
- Published by Elsevier in Science Bulletin
- Vol. 70 (21) , 3589-3599
Injectable self-healing hydrogels loaded with islet-integrated microfiber scaffolds for islet transplantation in diabetes mellitus
- 16 June 2025
- Published by Elsevier in Science Bulletin
- Vol. 70 (21) , 3589-3599
Injectable self-healing hydrogels loaded with islet-integrated microfiber scaffolds for islet transplantation in diabetes mellitus
- 5 May 2025
- Published by Elsevier in Endocrine Practice
- Vol. 31 (8) , 995-1001
Diagnostic Performance of Noninvasive Tests for Identifying Advanced Fibrosis in Metabolic Dysfunction-Associated Fatty Liver Disease With Mixed Etiologies
- 5 May 2025
- Published by Elsevier in Endocrine Practice
- Vol. 31 (8) , 995-1001
Diagnostic Performance of Noninvasive Tests for Identifying Advanced Fibrosis in Metabolic Dysfunction-Associated Fatty Liver Disease With Mixed Etiologies